drugset / Trial / NCT05554666
A Study of ASKG315 in Patients With Advanced Solid Tumors.
Phase 1
Unknown
56 enrolled
AskGene Pharma, Inc.
Jiangsu Aosaikang Pharmaceutical Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
The study is a Phase 1, open-label, multicenter, dose escalation study to evaluate the safety, tolerability, PK and PD of ASKG315 as a single agent in patients with advanced solid tumors.
Timeline
- Start
- 2022-10-15
- Primary completion
- 2023-12-31
- Completion
- 2024-10-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ASKG315 | Unknown | 3 mg | Intravenous |
| Subject | ASKG315 | Unknown | 45 mg | Intravenous |